[5].Hu Q, Oki E, Yamada T, Kashiwada T, Sonoda H, Kataoka M, Kawanaka H, Tsuji Y, Makiyama A, Nakashima Y, Ota M, Kimura Y, Yoshizumi T. Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial. Cancer Med. 2023 Jun 16. doi: 10.1...
1.Shen L, Peng Z, et al. Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA).2024 ESMO LBA60.2.Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical...
Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;193:104216. 审批编码:PP-SI-CN-1550 审批时间:2024 年 7 月 24 日 👇 点击阅读详细文献解读 👇 上下...
[6]Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer. 2016 Jan;5...
4. European Commission approves Merck’s Keytruda (pembrolizumab) plus chemotherapy for new first-line indications in advanced HER2-negative gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (CPS ≥1) and advanced biliary tract cancer. News release. Merck. December 18, 2023. Accessed April ...
[1] S. Y. Rha, et al. Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. ESMO Virtual Plenary202...
Trastuzumab inhibits growth of HER-2-negative gastric cancer cells through gastrin-initialized CCKBR signaling. Cui Y,Li SB,Peng XC,et al. Digestive Diseases and Sciences . 2015Cui Y, Li SB, Peng XC, Wu J, Fu GH (2015) Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells ...
1. S. Y. Rha, et al. Pembrolizumab plus chemotherapy as first-linetherapyfor advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. ESMO Virtual Plenary2023. 2. Zhao JJ, Yap DWT, Chan YH, et al. Low Programmed Death-Ligand 1-Expressing ...
Clin Cancer Res, 2021, 27(1):43-51. DOI:10.1158/1078-0432.CCR-20-2488. [9] Xu HY, Sheng XN, Zhou L, et al. A phase Ⅱ study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma[J]. J Clin Oncol, 2022, 40(Suppl 16):4519. DOI:...
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary... Purpose The intratumoural heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in gastric cancer is a major challenge wh...